跳至主要内容
临床试验/NCT03485651
NCT03485651终止不适用

Prospective Collection of Samples for Development of the Natera Ovarian Cancer Detection Assay

Natera, Inc.1 个研究点 分布在 1 个国家目标入组 12 人开始时间: 2017年12月14日最近更新:
适应症

试验速览

阶段
不适用
状态
终止
发起方
Natera, Inc.
入组人数
12
试验地点
1
主要终点
Compare ctDNA from benign ovarian masses and confirmed ovarian cancers

研究概览

简要总结

The purpose of this study is to enroll participants who present with an adnexal mass on imaging to develop a non-invasive ovarian cancer assay to distinguish between malignant and benign masses. The study will collect blood, tissue, and health information from these individuals.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Prospective

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Female
接受健康志愿者

入选标准

  • Presenting to clinic with adnexal mass suspicious of ovarian, fallopian tube, or peritoneal cancer on imaging
  • Must be planning surgical resection or biopsy
  • Must be treatment naïve
  • Must be 18 years or older
  • Able to understand and sign a written informed consent document
  • Able to provide 40mL of blood (at least 20mL) for each blood draw

排除标准

  • Prior removal of either ovary for any reason
  • Currently pregnant
  • Blood transfusion within 3 months of study enrollment
  • History of bone marrow or organ transplant
  • Prior history and treatment for any malignancy, with exception of previously treated non-melanoma skin cancer.
  • A medical condition that would place subject at risk as a result of the blood donation, including but not limited to bleeding disorders, chronic infectious disease, emphysema or serious anemia

结局指标

主要结局

Compare ctDNA from benign ovarian masses and confirmed ovarian cancers

时间窗: Up to 60 months or 5 years

Examine ctDNA between benign ovarian masses and confirmed ovarian cancer cases (based on tumor pathology report). The purpose of this outcome is to determine whether cfDNA could be used to develop a non-invasive ovarian cancer assay to distinguish between malignant and benign masses.

次要结局

  • Determine the relationship between quantity of ctDNA and standard prognostic criteria(Up to 60 months or 5 years)

研究者

发起方
Natera, Inc.
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验